Eisai Company, Ltd. Launches New Oral Jelly Formulation of Aricept(R), World’s First Oral Jelly for Alzheimer’s Disease Treatment

Tokyo, Dec 1, 2009 (JCN Newswire) - Eisai Co., Ltd. today announced the launch of a new formulation of its Alzheimer's disease (AD) treatment, Aricept(R) Oral Jelly 3mg, Aricept(R) Oral Jelly 5mg, and Aricept(R) Oral Jelly 10mg. The new products will be available on the Japanese market from December 2.